Company Overview
Lucyd, Inc is a specialized developer and manufacturer focused on the creation and commercialization of smart eyeglasses and sunglasses within the North American market. The company's flagship offering, the Lucyd Lyte, provides users with hands-free capabilities to listen to music, conduct voice calls, and utilize voice assistants or ChatGPT to execute smartphone tasks without holding a device. Operating within the Healthcare sector, specifically under the Medical Instruments & Supplies industry, the firm targets a niche that blends wearable technology with medical-grade supply chains, though the sector classification suggests broader applications for health-conscious consumers. The company currently holds a market capitalization of $5.78M and generated $2.66M in annual revenue over the trailing twelve months, while the total employee count is not publicly disclosed. These financial metrics indicate that Lucyd, Inc operates as a micro-cap entity with a relatively small revenue base, suggesting it is in an early-stage growth phase where capital allocation is heavily weighted toward product development and market penetration rather than mature operational scaling.
Financial Health
Lucyd, Inc reported a trailing twelve-month revenue of $2.66M, yet this top-line figure is accompanied by a significant net loss of $-7,591,189, revealing a cost structure where expenses substantially exceed current income generation. The company's EBITDA stands at $-8,359,622, which is lower than the net income figure, indicating that interest or tax adjustments, along with non-operating items, are influencing the bottom line differently than the core operational earnings. Free cash flow is reported at $-6,326,188, meaning the company is burning cash faster than it generates from operations, which limits immediate financial flexibility for expansion without external funding. The gross margin sits at 21.3%, showing that the company retains roughly one-fifth of revenue after direct costs, while the operating margin is a severe -260.4% and the profit margin is -285.2%, indicating that overhead and operational expenses are far exceeding the gross profit generated by sales. The firm holds $6.51M in cash and has no disclosed debt, creating a scenario where total cash vastly outweighs total debt, suggesting a balance sheet that is currently un-leveraged and reliant on cash reserves rather than borrowed capital. The current ratio is an impressive 9.03, which indicates that the company possesses a very high level of short-term liquidity, holding nearly ten times more current assets than current liabilities. Return on Equity is -83.6% and Return on Assets is -53.2%, metrics that reveal that management is currently destroying value per share and per asset unit, a common characteristic for pre-profitability biotech or tech hardware firms investing heavily in research and development.
Valuation Assessment
The company exhibits a trailing P/E ratio that is not applicable due to losses, while the forward P/E is listed as -1.05, implying that the market prices the stock based on future expectations of turning profitability or using alternative valuation drivers rather than current earnings multiples. The price-to-book ratio is 0.65, which indicates that the market values the company at roughly 65% of its book value, suggesting a market discount relative to the net asset position or a lack of confidence in near-term asset appreciation. The price-to-sales ratio is 2.17, and the EV/EBITDA is -0.04, suggesting that investors are valuing the firm primarily on its revenue generation capabilities rather than earnings power or enterprise value efficiency. The stock has traded between a 52-week high of $5.56 and a 52-week low of $0.95, and without a specific current price provided in the facts, the valuation range defines the maximum and minimum volatility bounds observed over the last year. The beta is not applicable or disclosed, meaning that the stock's price volatility relative to the broader market cannot be quantified using historical correlation data, leaving the risk profile undefined in terms of market sensitivity.
Growth & Income
Lucyd, Inc achieved a revenue growth rate of 39.0% year-over-year, while earnings growth is not applicable due to the company's negative earnings position, implying that top-line expansion is outpacing any potential for profitability in the short term. As a non-dividend payer, the company does not offer a dividend yield or a payout ratio, indicating that all available cash flow is being reinvested into operations, product development, and working capital rather than distributed to shareholders. This reinvestment strategy is typical for high-growth hardware companies that prioritize scaling their product line and capturing market share over providing immediate income to investors. The overall growth and income profile for Lucyd, Inc is characterized by aggressive revenue expansion and zero dividend income, reflecting a capital-intensive business model where shareholder returns are deferred in anticipation of future operational profitability.